"The Effect of the Use of an Autotransfusion Device on Hemodynamic Parameters During Resuscitation".

May 8, 2024 updated by: University Medical Centre Maribor

"The Effect of the Use of an Autotransfusion HemaShock Device on Hemodynamic Parameters During Resuscitation"

The purpose of the research (pilot study) is to determine the impact of the use of the autotransfusion device on hemodynamic parameters during resuscitation.

24 people will be included in the pilot study (12 people will be included in the intervention group - with the usage of "autotransfusion socks" during resuscitation and 12 people in the control group - without "autotransfusion socks"). Investigators will compare the hemodynamic parameters and also neurological outcome between both groups.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

The purpose of the research (pilot study) is to determine the impact of the use of the autotransfusion device on hemodynamic parameters during resuscitation.

Out-of-hospital cardiac arrest (OHCA) is one of the leading causes of death in Europe.

In order to improve the hemodynamic parameters during resuscitation, device for autotransfusion was developed. Devices are basically a very strong elastic stockings that also block arterial circulation. While "putting on" stockings, blood is being squeezed from the lower extremities (approximately 500 ml of blood for each lower limb). With blood being squeezed from the lower limb into the central circulation the filling of the heart is being improved; thus the device will improve the preload and also cardiac output.

A study done on an animal model showed that during resuscitation using "autotransfusion socks" increases both systolic and diastolic blood pressure during resuscitation, the perfusion of the coronary arteries improves and also the values of the partial pressure of carbon dioxide increases.

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Maribor, Slovenia, 2000
        • Recruiting
        • Community health center Maribor, Prehospital unit
        • Contact:
      • Maribor, Slovenia, 2000
        • Recruiting
        • Maribor University Medical Centre
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • OHCA (Out of Hospital Cardiac Arrest)
  • age > 18 years
  • intubated
  • meets criteria for resuscitation

Exclusion Criteria:

  • age < 18 years
  • not intubated
  • clinical signs for DVT (deep vein thrombosis), PE (pulmonary embolism)
  • clinical signs of acute inflammation of limbs, broken limbs etc.
  • known oncological patient
  • asphyxia
  • trauma patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patients with HemaShock device

12 patients in cardiac arrest will receive HemaShock device during resuscitation.

All other interventions will be made following guidelines.

The HemaShock is a tight silicone ring attached to a pressure stocking. It comes wrapped into a doughnut and has a set of handles. The operator simply puts the doughnut over the foot or hand, and pulls on the handles to unravel the HemaShock while applying pressure throughout the appendage. The device displace blood from limbs to central blood system, thus improving preload and cardiac output.
No Intervention: Patients with-out HemaShock device

12 patients in cardiac arrest will not receive HemaShock device during resuscitation.

All other interventions will be made following guidelines.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: Immediately after arrival to the victim
Non-invasive blood pressure (both systolic and diastolic blood pressure) will be measured.
Immediately after arrival to the victim
End tidal CO2 (Carbon dioxide) after intubation
Time Frame: Immediately after an intubation
capnography
Immediately after an intubation
End tidal CO2 (Carbon dioxide) after application of Hemashock Socks
Time Frame: Immediately after an application of Hemashock Socks
capnography
Immediately after an application of Hemashock Socks
End tidal CO2 (Carbon dioxide) every 5 minutes after first application of Hemashock Socks
Time Frame: 5 minutes after the first application of HemaShock socks
capnography
5 minutes after the first application of HemaShock socks
End tidal CO2 (Carbon dioxide) every 5 minutes after first application of Hemashock Socks
Time Frame: 10 minutes after the first application of HemaShock socks
capnography
10 minutes after the first application of HemaShock socks
End tidal CO2 (Carbon dioxide) every 5 minutes after first application of Hemashock Socks
Time Frame: 15 minutes after the first application of HemaShock socks
capnography
15 minutes after the first application of HemaShock socks
End tidal CO2 (Carbon dioxide) every 5 minutes after first application of Hemashock Socks
Time Frame: 20 minutes after the first application of HemaShock socks
capnography
20 minutes after the first application of HemaShock socks
End tidal CO2 (Carbon dioxide) every 5 minutes after first application of Hemashock Socks
Time Frame: 25 minutes after the first application of HemaShock socks
capnography
25 minutes after the first application of HemaShock socks
End tidal CO2 (Carbon dioxide) every 5 minutes after first application of Hemashock Socks
Time Frame: 30 minutes after the first application of HemaShock socks
capnography
30 minutes after the first application of HemaShock socks
End tidal CO2 (Carbon dioxide) after removal of HemaShock Socks
Time Frame: Immediately after the removal of HemaShock socks
capnography
Immediately after the removal of HemaShock socks
Blood pressure
Time Frame: Immediately after ROSC
Noninvasive blood pressure ((both systolic and diastolic blood pressure)) after removal of HemaShock Socks
Immediately after ROSC

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cerebral Performance Category Scale
Time Frame: Through study completion, an average of 1 year
Neurological outcome assessed with Cerebral Performance Category Scale (CPC). CPC 1-2 means good outcome, CPC 3-5 means poor outcome.
Through study completion, an average of 1 year
Tissue/skin malfunction under HemaShock Socks
Time Frame: From removal of the HemaShock socks up to 15 weeks
Irrigation, oedema, tissue malperfusion
From removal of the HemaShock socks up to 15 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 22, 2023

Primary Completion (Estimated)

December 30, 2024

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

February 28, 2023

First Submitted That Met QC Criteria

November 28, 2023

First Posted (Actual)

December 1, 2023

Study Record Updates

Last Update Posted (Actual)

May 9, 2024

Last Update Submitted That Met QC Criteria

May 8, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Arrest

Clinical Trials on HemaShock device

3
Subscribe